UCB PHARMA SA
๐ง๐ชBelgium
- Country
- ๐ง๐ชBelgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 279
- Registration Number
- NCT00263068
- Locations
- ๐บ๐ธ
Schwarz, RTP, North Carolina, United States
Determine Effects of Adjunctive Levetiracetam on Sleep Architecture in Adults With Partial Onset Epilepsy.
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 40
- Registration Number
- NCT00245713
Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-28
- Last Posted Date
- 2019-05-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 176
- Registration Number
- NCT00245765
Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-26
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 506
- Registration Number
- NCT00244387
- Locations
- ๐ฉ๐ช
Schwarz, Monheim, Germany
Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ยฎ on Prescription
Completed
- Conditions
- First Posted Date
- 2005-10-26
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 750
- Registration Number
- NCT00244465
- Locations
- ๐ฉ๐ช
22, Bremen, Germany
๐ฎ๐ช4, Dublin 7, Ireland
๐ฉ๐ช24, Berlin, Germany
A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00243971
- Locations
- ๐ฉ๐ช
Schwarz, Monheim, Germany
A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 58
- Registration Number
- NCT00243945
- Locations
- ๐ฉ๐ช
Schwarz, Monheim, Germany
Rotigotine Restless Legs Syndrome Dose Finding Trial
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 341
- Registration Number
- NCT00243217
- Locations
- ๐ฉ๐ช
Schwarz, Monheim, Germany
A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00242008
- Locations
- ๐บ๐ธ
Schwarz, RTP, North Carolina, United States
An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00238511
- Locations
- ๐ฉ๐ช
Schwarz, Monheim, Germany
ยฉ Copyright 2024. All Rights Reserved by MedPath